Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true, idempotentHint=true, destructiveHint=false and a closed-world scope, so the safety profile is fully covered. The description adds real value by disclosing that the result is a union of three heterogeneous sources, but says nothing about result volume, matching breadth, or missing-data behavior for a firm with no FDA footprint.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

A single front-loaded sentence with an em-dash list; every clause carries information (scope, entity type, the three constituent datasets) and there is no filler or repetition.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description compensates reasonably by naming exactly which record types come back, which is the key thing an agent needs to judge relevance. A brief note on response shape or per-source grouping would close the remaining gap, but it is largely complete for a one-parameter aggregation tool.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% and the single parameter's substring/case-insensitivity semantics are already documented in the schema. The description only reinforces the single-firm scope ('one firm') without adding syntax or matching guidance beyond what the schema provides, so the baseline 3 applies.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a clear verb+resource ('All FDA activity for one firm') and enumerates the three datasets it unions (recalls, 510(k) clearances, FAERS reports), which visibly separates it from single-dataset FDA siblings like drug_label. It does not, however, explicitly name or contrast any sibling tool.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

Usage is implied by 'for one firm' and 'All FDA activity' — i.e., use this for a firm-level rollup rather than a single FDA dataset — but there is no explicit when-to-use/when-not or named alternative (e.g., drug_label for labels, clinical_trials_recent for trials). The scoping hint is present but the routing guidance is left to inference.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.